Bausch + Lomb (NYSE:BLCO) & Nuwellis (NASDAQ:NUWE) Head-To-Head Analysis

Bausch + Lomb (NYSE:BLCO) and Nuwellis (NASDAQ:NUWE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Bausch + Lomb and Nuwellis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-2.05%	5.01%	2.34%
Nuwellis	-123.38%	-623.14%	-147.34%

Analyst Ratings

This is a summary of recent recommendations and price targets for Bausch + Lomb and Nuwellis, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	7	5	1	2.43
Nuwellis	1	0	0	0	1.00

Bausch + Lomb currently has a consensus price target of $20.75, indicating a potential upside of 3.80%. Given Bausch + Lomb’s stronger consensus rating and higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Nuwellis.

Risk & Volatility

Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by company insiders. Comparatively, 1.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bausch + Lomb and Nuwellis”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.42 billion	1.32	-$360.00 million	($0.31)	-64.48
Nuwellis	$8.27 million	0.37	-$17.52 million	($132.59)	-0.04

Nuwellis has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Summary

Bausch + Lomb beats Nuwellis on 12 of the 15 factors compared between the two stocks.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

About Nuwellis

Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company offers Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure. Its Aquadex FlexFlow system includes a console, disposable blood circuit set, and disposable catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors in Austria, Belarus, Brazil, Colombia, the Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Panama, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.